Bayer HealthCare’s oral anticoagulant tablet Xarelto (rivaroxaban) has been recommended for NHS use in final guidance from the National Institute for Health and Clinical Excellence (NICE), for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors.
The guidance advises that the drug should be considered as a therapeutic option in non-valvular AF patients with one or more stroke risk factors, such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, and prior stroke or transient ischaemic attack (TIA).
